Given the immune background, we hypothesize that active Grave's hyperthyroidism is a risk factor for an acute phase reaction associated with the use of bisphosphonates. We recommend that in patients with Graves' thyrotoxicosis and hypercalcemia, consider the risk of an acute phase reaction if planning to give bisphosphonate therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538055 | PMC |
| http://dx.doi.org/10.1002/ccr3.1022 | DOI Listing |
Publication Analysis
Top Keywords
acute phase
12
phase reaction
12
reaction intravenous
4
intravenous bisphosphonate
4
bisphosphonate patient
4
patient diagnosed
4
diagnosed graves'
4
graves' disease
4
disease immune
4
immune background
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!